Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5452MR)

This product GTTS-WQ5452MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_009902072.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299391
UniProt ID P16154
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5452MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13745MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ9875MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ4999MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ13406MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ10083MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ9616MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ7095MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ6506MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-072
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW